Equities analysts expect IntriCon Co. (NASDAQ:IIN) to report sales of $28.18 million for the current quarter, Zacks reports. Two analysts have made estimates for IntriCon’s earnings, with the highest sales estimate coming in at $28.26 million and the lowest estimate coming in at $28.10 million. IntriCon posted sales of $30.13 million in the same quarter last year, which suggests a negative year over year growth rate of 6.5%. The company is expected to issue its next earnings report on Monday, November 4th.

On average, analysts expect that IntriCon will report full-year sales of $116.19 million for the current year, with estimates ranging from $116.17 million to $116.20 million. For the next financial year, analysts anticipate that the business will post sales of $130.09 million, with estimates ranging from $130.00 million to $130.18 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for IntriCon.

IntriCon (NASDAQ:IIN) last posted its earnings results on Tuesday, August 6th. The technology company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.59). IntriCon had a negative net margin of 1.23% and a positive return on equity of 4.21%. The firm had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.32 million.

A number of research firms have weighed in on IIN. ValuEngine raised IntriCon from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 5th. Zacks Investment Research raised IntriCon from a “sell” rating to a “hold” rating in a report on Saturday, August 3rd. B. Riley set a $36.00 target price on IntriCon and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Stifel Nicolaus set a $36.00 target price on IntriCon and gave the company a “buy” rating in a report on Friday, July 19th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. IntriCon presently has a consensus rating of “Buy” and a consensus price target of $38.75.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bard Associates Inc. raised its stake in shares of IntriCon by 4.9% in the second quarter. Bard Associates Inc. now owns 28,195 shares of the technology company’s stock worth $659,000 after buying an additional 1,325 shares during the period. Vanguard Group Inc. raised its stake in shares of IntriCon by 0.4% in the second quarter. Vanguard Group Inc. now owns 420,572 shares of the technology company’s stock worth $9,825,000 after buying an additional 1,470 shares during the period. BNP Paribas Arbitrage SA bought a new position in shares of IntriCon in the first quarter worth about $40,000. First Mercantile Trust Co. bought a new position in shares of IntriCon in the second quarter worth about $76,000. Finally, US Bancorp DE raised its stake in shares of IntriCon by 6.4% in the first quarter. US Bancorp DE now owns 60,344 shares of the technology company’s stock worth $1,513,000 after buying an additional 3,650 shares during the period. 77.66% of the stock is currently owned by hedge funds and other institutional investors.

IIN stock traded up $0.27 during trading on Friday, reaching $20.25. The stock had a trading volume of 56,915 shares, compared to its average volume of 148,890. IntriCon has a 52 week low of $16.81 and a 52 week high of $68.15. The stock’s 50 day moving average is $18.07 and its two-hundred day moving average is $22.58. The company has a current ratio of 3.02, a quick ratio of 2.19 and a debt-to-equity ratio of 0.03. The firm has a market cap of $177.27 million, a PE ratio of 31.64, a PEG ratio of 7.67 and a beta of 0.72.

IntriCon Company Profile

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.

Featured Article: How to Invest in Stocks with Increasing Dividends

Get a free copy of the Zacks research report on IntriCon (IIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IntriCon (NASDAQ:IIN)

Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.